487基因表达谱检测指导特应性皮炎系统治疗选择:一项前瞻性试验结果
本研究开发并验证了487基因表达谱(487-GEP)检测,用于指导特应性皮炎(AD)系统治疗选择。前瞻性研究纳入AD或银屑病患者皮损刮取物行RNA-Seq,构建集成算法分类治疗应答概率,并在AD患者中独立验证。结果显示,487-GEP分类为JAK抑制剂应答者 profile 的AD患者接受JAKi治疗后EASI-90率、无瘙痒率及无复发率显著优于Th2靶向治疗,且应答速度更快;而Th2分子 profile 患者两种治疗无显著差异。
要点
- 487-GEP可识别更可能从JAK抑制剂而非Th2靶向治疗中获益的AD患者。
- JAKi应答者 profile 患者接受JAKi治疗EASI-90率达45.5%,显著高于Th2靶向治疗的8.3%。
- Th2分子 profile 患者使用Th2靶向或JAKi的EASI-90率无统计学差异。
核心结论
- 487-GEP检测能够识别出比Th2靶向治疗更可能从JAK抑制剂中获益的AD患者。
研究设计与样本
- 前瞻性研究,对AD或银屑病皮损皮肤刮取物进行RNA-Seq分析,并报告治疗与结局。
- 开发集成算法(12个神经网络,487个基因,即487-GEP)分类AD或银屑病治疗应答概率(n=192),并在AD患者(n=110)中独立验证。
主要发现
- 487-GEP分类为JAK抑制剂应答者 profile 的AD患者占30.4%,接受JAKi治疗相比Th2靶向治疗,EASI-90率显著更高(45.5% vs 8.3%,P=.021),应答速度快3.8倍(P=.049)。
- 上述JAKi应答者 profile 患者中,报告「无瘙痒」的比例为45.5% vs 8.3%(P=.021),无复发率增加(54.5% vs 16.7%,P=.041)。
- 对于Th2分子 profile 患者,使用Th2靶向治疗(26.5%)或JAKi(33.3%)的EASI-90率无统计学差异(P=.728)。
临床怎么用
- 临床可考虑使用487-GEP检测辅助AD系统治疗选择,优先为JAKi应答者 profile 患者选用JAK抑制剂。
- Th2分子 profile 患者选择Th2靶向治疗或JAKi时,EASI-90率无显著差异,可结合其他因素决策。
局限性
- 验证仅限于年龄≥12岁的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current atopic dermatitis (AD) therapy selection does not account for molecular drivers of disease, contributing to inadequate disease control for half of patients. OBJECTIVE: Develop and validate a gene expression profile (GEP) test to guide AD systemic therapy selection. METHODS: In a prospective study, AD or psoriasis lesion skin scrapings were analyzed by RNA-Seq, and treatments and outcomes including Eczema Area and Severity Index, itch, and flare frequency were reported. An ensemble algorithm (12 neural networks with 487 genes, 487-GEP) was developed to classify the probability of AD or psoriasis treatment response (n = 192) and independently validated in AD patients (n = 110). RESULTS: AD patients classified by the 487-GEP as JAK inhibitor (JAKi) Responder Profile (30.4%) and treated with a JAKi achieved significantly higher rates of Eczema Area and Severity Index-90 (45.5% vs 8.3%, P = .021) 3.8 times faster (P = .049), reported "no itch" (45.5% vs 8.3%, P = .021), and increased flare-free rate (54.5% vs 16.7%, P = .041) versus Th2-targeted therapy. For those with a Th2 Molecular Profile, there were no statistical differences in Eczema Area and Severity Index-90 whether they used Th2-targeted (26.5%) or JAKi (33.3%, P = .728). LIMITATIONS: Validation was limited to patients ≥12 years. CONCLUSIONS: The 487-GEP identifies AD patients more likely to benefit from JAKi than Th2-targeted therapies.
引用
- Silverberg JI, Eichenfield LF, Armstrong AW, et al. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial. J Am Acad Dermatol. 2026. PMID: 41707702. doi:10.1016/j.jaad.2026.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。